Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 11.1% – Time to Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares traded down 11.1% during mid-day trading on Thursday . The stock traded as low as $0.26 and last traded at $0.26. 72,709,392 shares were traded during trading, a decline of 5% from the average session volume of 76,777,180 shares. The stock had previously closed at $0.29.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research note on Thursday. They issued a “hold” rating for the company.

Tonix Pharmaceuticals Trading Down 11.1 %

The firm has a market cap of $47.84 million, a PE ratio of 0.00 and a beta of 2.02. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The company has a 50 day simple moving average of $0.25 and a two-hundred day simple moving average of $0.33.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $1.80. The company had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. Analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.